Key Highlights

● ArriVent BioPharma plunged to about $15.59.

● Caribou Biosciences tumbled to about $0.61 after hours.

● Vaxcyte launched a $500 million stock offering plus $500 million of convertible notes.

● Only 48 of 428 Russell 2000 health-care stocks advanced.

Small biotech stocks had one of the worst days of any group on Tuesday, Oct. 6. The sharpest fall came at ArriVent BioPharma (NASDAQ:AVBP), which plunged to about $15.59 in the heaviest loss among small and mid-sized health-care stocks.

After the closing bell, Caribou Biosciences (NASDAQ:CRBU) tumbled in extended trading to about $0.61.

Other declines were broad. CG Oncology (NASDAQ:CGON) slid to about $63.94 and OmniAb (NASDAQ:OABI) fell to about $4.44. Diagnostics companies GRAIL (NASDAQ:GRAL) and GeneDx (NASDAQ:WGS) dropped as well. Only 48 of 428 health-care holdings in the Russell 2000 advanced on the day.

Vaccine stocks give back gains

Vaccine makers added to the pressure. Novavax (NASDAQ:NVAX) fell sharply after the World Health Organization downgraded the risk from a pneumonic plague outbreak to low. Larger peer Moderna (NASDAQ:MRNA) also tumbled, closing at $187.46.

Vaxcyte (NASDAQ:PCVX) slid early after launching an offering of $500 million of common stock and pre-funded warrants plus $500 million of convertible notes due 2032. The sale followed a sharp rally on Monday after Phase 3 data showed its VAX-31 Vaccine "met all prespecified co-primary immunogenicity endpoints in adults 50 and older," according to the company's prospectus. Biotech companies often raise money after positive data, when their share prices are higher, and new share sales can weigh on the stock in the short term.

A few winners and analyst calls

Not everything fell. Prime Medicine (NASDAQ:PRME) jumped to about $3.71 and Ginkgo Bioworks (NYSE:DNA) soared to about $17.64. Pacific Biosciences (NASDAQ:PACB) rose after announcing a research collaboration with TychoBio.

Analysts were active. Guggenheim initiated or assumed coverage at Buy on several companies, including Neurocrine Biosciences (NASDAQ:NBIX), Xenon Pharmaceuticals (NASDAQ:XENE), Rapport Therapeutics (NASDAQ:RAPP) and Ovid Therapeutics (NASDAQ:OVID). Cantor Fitzgerald upgraded Rezolute (NASDAQ:RZLT) to Overweight, and H.C. Wainwright upgraded Crescent Biopharma (NASDAQ:CBIO) to Buy. Barclays (NYSE:BCS) started Intellia Therapeutics (NASDAQ:NTLA) at Underweight.

Why small biotech is so volatile

Small biotech companies often have no product Revenue and rely on a handful of experimental drugs. Their value depends heavily on clinical trial results, regulatory decisions and their ability to raise cash. That makes their shares prone to sharp moves, sometimes without a clear trigger, and sensitive to shifts in investor appetite for risk.

Funding costs matter, too. The Federal Reserve raised its target range to 3.75 to 4.00 in September, and higher rates make it more expensive for cash-burning companies to raise money. Treasury yields eased on Tuesday, with the 10-year near 5.28, but that was not enough to lift the group.

The broader picture made the contrast stark. The S&P 500 rose 44.98 points to a record 7,818.93, and the Nasdaq Composite also closed at a record just under 27,600. The Dow Jones Industrial Average gained 253.38 points to 51,521.28. But the Russell 2000 fell about 17 points to roughly 2,830, and health care was the only S&P 500 sector to decline.

Company Updates and the WHO Will Steer Biotech Next

Investors will watch for any company updates from ArriVent and Caribou. Updates from the WHO on the plague outbreak could move vaccine stocks again. More broadly, September consumer price data on Oct. 14 and the Fed's Oct. 27-28 meeting will shape the Cost of Capital that small biotech companies depend on.